BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260515T071329EDT-1617V4ZNEW@132.216.98.100
DTSTAMP:20260515T111329Z
DESCRIPTION:Registration is required.\n\nThis event will feature two intern
 ational speakers. First\, Dr. Koen Venema of Wageningen University\, who s
 pecializes in validated in vitro models of the gut\, which he has used to 
 study the effects of prebiotics\, drugs\, and other components on the gut 
 microbiota.\n\nThe important role that the gut microbiota plays in health 
 and disease of the host has clearly been established over the last couple 
 of decades. Dysbiosis of the gut microbiota composition has been shown in 
 many different diseases. However\, dysbiosis is ill defined\, as it sugges
 ts that we know what a healthy gut microbiota is\, and that is not the cas
 e. The gut microbiota composition shows large inter-individual differences
  that are primarily defined by host genetics\, diet\, lifestyle and use of
  medication. On a functional level however\, the similarities between indi
 viduals are thought to be much higher\, due to large functional overlaps b
 etween different microbial taxa. Modelling the gut microbiota in sophistic
 ated in vitro models has become an important aspect of understanding the w
 ays that the composition and functionality of the microbiota can be modula
 ted. Use of highly sophisticated\, validated and predictive dynamic models
  of the GI-tract have resulted in tremendous insight in the mechanisms of 
 gut microbiota action. Production of beneficial and toxic metabolites can 
 be quantified in these systems\, which is almost impossible in vivo due to
  ethical constraints. Effects on composition and functionality can be stud
 ied much better in these systems as the experimental settings can be highl
 y controlled: single parameters can be changed and effects on microbiota m
 odulation can be observed. Detailed information such as substrate-specific
 ity\, dose-response\, antagonism or synergy between substrates\, or metabo
 lite production can be elucidated.\n\nFollowing the first session\, Ewa Hu
 dson\, Director of insights at NutraIngredients\, will explore critical qu
 estions shaping the industry: how to build a successful biotic portfolio a
 nd product roadmap\, which health applications and demographics offer the 
 most promising targets\, and how do branded pro/pre/postbiotics stack up a
 gainst generics in consumer engagement?\n\nIn today's rapidly evolving bio
 tic market\, product development has never been more complex—or more cruci
 al. With Lumina tracking 10 target populations\, 100 health benefits\, and
  90 biotic ingredient types\, brands face a staggering 90\,000 potential p
 roduct combinations. This presentation delves into the science-driven prol
 iferation of biotics\, highlighting emerging trends and innovation opportu
 nities.\n
DTSTART:20241121T140000Z
DTEND:20241121T153000Z
LOCATION:Zoom Virtual Meeting
SUMMARY:Lallemand Lecture Series - Gut Microbiota: Impact on Health\, Disea
 se and the Strategic Role of Biotics
URL:https://www.mcgill.ca/consortium-rita/Lallemand%20Lecture%20Series%201
END:VEVENT
END:VCALENDAR